Product Program year 2025 Source: CMS Open Payments

Saphnelo

Biological Inflammation and Autoimmunity

NDC 0310-3040-00

Open in the dashboard

General payments

$11,245,193

70,442 payments

Research payments

$49,796,455

1,987 payments

Through program year 2025, $11,245,193 in general payments and $49,796,455 in research payments were reported against Saphnelo (Inflammation and Autoimmunity).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

10 rows
Year Kind Amount Payments
2025 General $2,762,246 16,805
2025 Research $23,551,810 647
2024 General $2,604,979 16,404
2024 Research $13,478,563 432
2023 General $2,821,476 16,651
2023 Research $5,816,608 319
2022 General $2,183,760 14,429
2022 Research $5,214,909 378
2021 General $872,731 6,153
2021 Research $1,734,565 211

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $9,866,781 69,573 payments
  2. AstraZeneca UK Limited $1,378,411 869 payments
Top recipients General payments · program year 2025
  1. Dinesh Khanna Rheumatology · Ann Arbor, MI $100,985 4% · 26 payments
  2. Andrew Sulich Rheumatology · Saint Clair Shores, MI $95,568 3% · 104 payments
  3. Gordon Lam Rheumatology · Charlotte, NC $78,141 3% · 83 payments
  4. Surya Seshan New York, NY $67,050 2% · 2 payments
  5. Donald Thomas Rheumatology · Greenbelt, MD $66,882 2% · 67 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Rheumatology Internal Medicine $2,016,554 78% · 1,773 practitioners
  2. Dermatology $127,915 5% · 31 practitioners
  3. Internal Medicine $91,196 4% · 161 practitioners
  4. Physician Assistant $83,765 3% · 311 practitioners
  5. Anatomic Pathology & Clinical Pathology Pathology $82,350 3% · 2 practitioners

The top 5 of 70 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $399,990 14% · 304 recipients
  2. Texas $300,235 11% · 415 recipients
  3. New York $251,584 9% · 239 recipients
  4. Michigan $233,696 8% · 99 recipients
  5. Florida $183,620 7% · 358 recipients

The top 5 of 50 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

1,605

Prescriptions dispensed, refills included

Drug cost

$8,120,271

Paid at the pharmacy, in all

Prescribers

92

With 11 or more claims of it

Medicare Part D drugs matched to SAPHNELO, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Saphnelo Anifrolumab-Fnia Same name 92 1,605 $8,120,271

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 92 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Bikramjit Ahluwalia Internal Medicine CA 56 $265,739 $295
Victoria Katz Rheumatology NY 46 $222,558 $350
Jun Kang Dermatology MD 35 $183,014 None on record
Angela Stupi Rheumatology PA 35 $176,287 $243
Lauren Wire Nurse Practitioner OH 34 $174,198 $196

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 92 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to SAPHNELO
Billing code Providers Services Paid by Medicare
Injection, anifrolumab-fnia, 1 mg J0491 13 280,825 $3,753,011

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

70,442 general · 1,987 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record